United Therapeutics Corporation (UTHR) Stock Analysis — Probabli.AI
AI-powered analysis for UTHR (United Therapeutics Corporation): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
Last price: $579.54 · Market cap: $24.6B · AI outlook: Bullish
United Therapeutics Corporation is well-positioned for future growth due to its strong drug pipeline, recent FDA approvals, and expansion into international markets. Despite near-term challenges such as supply chain issues and equity issuance, its innovative product strategy and potential for clinical and market successes lead us to maintain a bullish outlook.
Probabilistic 1-Year Outlook
- Bull 50% · Neutral 30% · Bear 20%
- 1-year price estimates — P10: $500 / P50: $650 / P90: $775
- United Therapeutics is showing strong growth fundamentals with significant recent developments, particularly FDA approval for a new drug. This positions the stock for potential upside. However, issues such as supply…
5-Year Outlook
- Bull 65% · Neutral 25% · Bear 10%
- 5-year price estimates — P10: $460 / P50: $1,030 / P90: $1,450
SWOT Highlights
- Strength: Innovative drug pipeline
- Strength: FDA-approved treatments
- Risk: Average EPS surprises negative
- Risk: Recent equity raise may dilute existing shareholders
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
14 Wall Street analysts rate UTHR a BUY with a mean price target of $583.36.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
UTHR forecast details · UTHR sentiment details · UTHR insider activity
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.